TY - JOUR
T1 - Cefotaxime vs Nafcillin and Tobramycin for the Treatment of Serious Infection
T2 - Comparative Cost-effectiveness
AU - Moore, Richard D.
AU - Smith, Craig R.
AU - Holloway, James J.
AU - Lietman, Paul S.
PY - 1986/6
Y1 - 1986/6
N2 - • To evaluate the cost-effectiveness of cefotaxime sodium at a dosage of 12 g/day vs nafcillin sodium and tobramycin sulfate for the treatment of serious infection, the hospital and physician charges of patients enrolled in a prospective, randomized, clinical trial were analyzed. For 187 patients receiving therapy empirically, mean hospital charges for the interval in which the trial antibiotics were used were $3,550±$1,740 for cefotaxime and $3,160±$1,990 for nafcillin and tobramycin. After adjusting for cost-generating factors, charges for cefotaxime were greater than for nafcillin and tobramycin, but the difference was not significant. For 107 patients with clinically or bacteriologically documented infection, mean charges were $3,980±$1,800 for cefotaxime and $4,170±$1,780 for nafcillin and tobramycin. Adjusted charges did not differ. Incremental charges for cefotaxime per additional response were $1,630 in all patients and -$820 in patients with clinically or bacteriologically documented infections.
AB - • To evaluate the cost-effectiveness of cefotaxime sodium at a dosage of 12 g/day vs nafcillin sodium and tobramycin sulfate for the treatment of serious infection, the hospital and physician charges of patients enrolled in a prospective, randomized, clinical trial were analyzed. For 187 patients receiving therapy empirically, mean hospital charges for the interval in which the trial antibiotics were used were $3,550±$1,740 for cefotaxime and $3,160±$1,990 for nafcillin and tobramycin. After adjusting for cost-generating factors, charges for cefotaxime were greater than for nafcillin and tobramycin, but the difference was not significant. For 107 patients with clinically or bacteriologically documented infection, mean charges were $3,980±$1,800 for cefotaxime and $4,170±$1,780 for nafcillin and tobramycin. Adjusted charges did not differ. Incremental charges for cefotaxime per additional response were $1,630 in all patients and -$820 in patients with clinically or bacteriologically documented infections.
UR - http://www.scopus.com/inward/record.url?scp=0022539675&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022539675&partnerID=8YFLogxK
U2 - 10.1001/archinte.1986.00360180159024
DO - 10.1001/archinte.1986.00360180159024
M3 - Article
C2 - 3087307
AN - SCOPUS:0022539675
SN - 0003-9926
VL - 146
SP - 1153
EP - 1157
JO - Archives of internal medicine
JF - Archives of internal medicine
IS - 6
ER -